New Treatment Combo for Chronic Myeloid Leukemia and Related Acute Leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of four drugs (FLAG-IDA, venetoclax, asciminib, and possibly blinatumomab) for people with chronic myeloid leukemia or acute myeloid leukemia that carry a specific genetic change called the Philadelphia chromosome. The goal is to see if this combination can help people achieve remission and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–70 years old
- Have newly diagnosed or relapsed/refractory chronic myeloid leukemia or acute myeloid leukemia with the Philadelphia chromosome
- Adequate function of liver, kidneys, heart, and pancreas (based on blood tests and heart imaging)
- Have not previously failed asciminib treatment or the combination of intensive chemotherapy plus venetoclax
- No severe heart problems, recent heart attack, stroke, serious irregular heartbeats, or uncontrolled infections
- Willing and able to use reliable birth control (if able to become pregnant or father children) and commit to study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
Hear when a new Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.